Vanguard Group Inc. Trims Stock Position in Krystal Biotech, Inc. $KRYS

Vanguard Group Inc. reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,778,845 shares of the company’s stock after selling 13,363 shares during the quarter. Vanguard Group Inc. owned approximately 9.58% of Krystal Biotech worth $685,096,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Sound Income Strategies LLC increased its position in Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after purchasing an additional 127 shares during the period. Bessemer Group Inc. increased its position in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the period. Salomon & Ludwin LLC purchased a new position in Krystal Biotech during the 3rd quarter valued at $33,000. Danske Bank A S purchased a new position in Krystal Biotech during the 3rd quarter valued at $35,000. Finally, MAI Capital Management increased its position in Krystal Biotech by 79.7% during the 3rd quarter. MAI Capital Management now owns 284 shares of the company’s stock valued at $50,000 after purchasing an additional 126 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on KRYS. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Zacks Research downgraded shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Wolfe Research assumed coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They issued a “peer perform” rating on the stock. Finally, Chardan Capital upped their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $326.25.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the transaction, the chief accounting officer owned 22,366 shares in the company, valued at $5,985,141.60. The trade was a 3.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel Janney sold 11,803 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $275.59, for a total transaction of $3,252,788.77. Following the completion of the transaction, the director owned 73,293 shares in the company, valued at approximately $20,198,817.87. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 129,164 shares of company stock valued at $34,538,578 over the last 90 days. 13.10% of the stock is owned by corporate insiders.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $266.04 on Monday. The firm’s 50-day moving average price is $261.72 and its 200-day moving average price is $246.50. The company has a market capitalization of $7.83 billion, a PE ratio of 38.84 and a beta of 0.50. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. Equities analysts anticipate that Krystal Biotech, Inc. will post 7.58 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.